Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071526 | 1.00 | CHRM2 (0.81) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9702944 | 0.98 | CHRM2 (0.79) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| SCHEMBL9777412 | 0.98 | CHRM2 (0.79) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3626828 | 0.98 | CHRM2 (0.79) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| SCHEMBL348655 | 0.98 | CHRM2 (0.78) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| SCHEMBL9188072 | 0.94 | CHRM2 (0.86) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL10617762 | 0.92 | CHRM2 (0.83) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| SCHEMBL9777405 | 0.92 | CHRM2 (0.83) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| SCHEMBL9184672 | 0.92 | CHRM2 (0.89) | CHRM2SIRT2ALOX15KDM4EALDH1A1 | |
| SCHEMBL8508005 | 0.91 | CHRM2 (0.69) | CHRM2SIRT2ALOX15KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576032-B2 | Liquid clonidine extended release composition | TRIS PHARMA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250134883-A1 | NOVEL COMPOSITIONS | ARTISAN THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469027-A2 | NOVEL COMPOSITIONS | Tulex Pharmaceuticals Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118984699-A | Novel compositions | 图莱克斯制药公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240207189-A1 | LIQUID CLONIDINE EXTENDED RELEASE COMPOSITION | TRIS PHARMA, INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11918689-B1 | Liquid clonidine extended release composition | TRIS PHARMA INC (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2023147443-A2 | NOVEL COMPOSITIONS | TULEX PHARMACEUTICALS INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230165837-A1 | NOVEL CLONIDINE FORMULATION | PROVIDENT BANK | 2023-06-01 | — | — | US | disclosed |
| US-20220257780-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | BRILLIAN PHARMA INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-4041309-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | Brillian Pharma Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20120148672-A1 | ABUSE RESISTANT OPIOID DRUG-ION EXCHANGE RESIN COMPLEXES HAVING HYBRID COATINGS | TRIS PHARMA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120135077-A1 | ABUSE RESISTANT OPIOID DRUG-ION EXCHANGE RESIN COMPLEXES HAVING HYBRID COATINGS | TRIS PHARMA, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2428205-A1 | Modified release formulations containing drug-ion exchange resin complexes | Tris Pharma, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120015030-A1 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES | TRIS PHARMA, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8062667-B2 | Modified release formulations containing drug-ion exchange resin complexes | TRIS PHARMA, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100166858-A1 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES | TRIS PHARMA, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090317488-A1 | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof | TRIS PHARMA, INC (US) | 2009-12-24 | — | — | US | disclosed |
| US-20070215511-A1 | Modified release formulations containing drug-ion exchange resin complexes | TRIS PHARMA, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2003082892-A1 | IMPROVED APPARATUS, METHODS AND COMPOSITIONS FOR BIOTECHNICAL SEPARATIONS | TECHNOLOGY LICENSING CO. LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20020010145-A1 | Apparatus, methods and compositions for biotechnical separations | WILLSON RICHARD C (US) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576032-B2 | Liquid clonidine extended release composition | SLC6A2, SLC6A3, SLC18A2 | CHRM2 79/4885SIRT2 3763/4885ALOX15 4250/4885 |
| US-20230165837-A1 | NOVEL CLONIDINE FORMULATION | SLC18A1, SLC6A2, SLC18A2 | CHRM2 106/4885SIRT2 3703/4885ALOX15 4067/4885 |
| US-11918689-B1 | Liquid clonidine extended release composition | SLC18A1, SLC18A2, CRH | CHRM2 98/4885SIRT2 4185/4885ALOX15 3354/4885 |
| US-20240207189-A1 | LIQUID CLONIDINE EXTENDED RELEASE COMPOSITION | SLC18A1, SLC18A2, CRH | CHRM2 98/4885SIRT2 4185/4885ALOX15 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.